Definitive Healthcare (NASDAQ:DH) Issues FY 2022 Earnings Guidance

Definitive Healthcare (NASDAQ:DHGet Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.22-$0.26 for the period, compared to the consensus estimate of $0.24. The company issued revenue guidance of $220.50 million-$224.50 million, compared to the consensus revenue estimate of $220.48 million.Definitive Healthcare also updated its Q2 2022 guidance to $0.04-$0.05 EPS.

Shares of Definitive Healthcare stock opened at $16.47 on Monday. The company has a current ratio of 3.21, a quick ratio of 3.21 and a debt-to-equity ratio of 0.18. The business’s 50 day simple moving average is $22.68 and its 200-day simple moving average is $25.12. Definitive Healthcare has a twelve month low of $14.76 and a twelve month high of $50.30.

Definitive Healthcare (NASDAQ:DHGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $46.31 million for the quarter, compared to analyst estimates of $44.78 million. Research analysts anticipate that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on DH shares. Zacks Investment Research cut Definitive Healthcare from a hold rating to a sell rating in a research report on Wednesday, May 18th. Canaccord Genuity Group raised Definitive Healthcare from a hold rating to a buy rating in a report on Thursday, February 24th. Deutsche Bank Aktiengesellschaft increased their price objective on Definitive Healthcare from $21.00 to $26.00 and gave the stock a hold rating in a report on Tuesday, April 5th. Canaccord Genuity Group raised Definitive Healthcare from a hold rating to a buy rating and decreased their price objective for the stock from $46.00 to $28.00 in a report on Thursday, February 24th. Finally, Barclays decreased their price objective on Definitive Healthcare from $26.00 to $23.00 in a report on Thursday, February 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $37.00.

In other Definitive Healthcare news, CFO Richard Douglas Booth bought 2,374 shares of Definitive Healthcare stock in a transaction dated Thursday, March 3rd. The stock was bought at an average price of $21.06 per share, for a total transaction of $49,996.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Charles Haywood sold 18,315 shares of the stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $15.46, for a total value of $283,149.90. The disclosure for this sale can be found here. 17.52% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in DH. BlackRock Inc. raised its holdings in shares of Definitive Healthcare by 50.4% during the fourth quarter. BlackRock Inc. now owns 2,256,587 shares of the company’s stock worth $61,672,000 after acquiring an additional 756,587 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Definitive Healthcare by 1,601.9% during the first quarter. Bank of New York Mellon Corp now owns 557,676 shares of the company’s stock worth $13,746,000 after acquiring an additional 524,908 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Definitive Healthcare by 17.8% during the first quarter. Clearbridge Investments LLC now owns 2,077,794 shares of the company’s stock worth $51,218,000 after acquiring an additional 314,089 shares in the last quarter. Geode Capital Management LLC increased its position in Definitive Healthcare by 265.3% during the fourth quarter. Geode Capital Management LLC now owns 333,018 shares of the company’s stock worth $9,101,000 after buying an additional 241,849 shares during the last quarter. Finally, State Street Corp acquired a new position in Definitive Healthcare during the fourth quarter worth $4,153,000. Institutional investors and hedge funds own 99.42% of the company’s stock.

About Definitive Healthcare (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

See Also

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.